Frequency of hepatocellular carcinoma in patients with hepatitis C received treatment with directly antiviral agents

Ubedullah Bughio; Adil Hassan Chang; Rahmatullah Bhatti; Bushra Kadir; Muhammad Sadik Memon; Saadat Ali; Mashooque Samejo; Sidra Dars

doi:10.53730/ijhs.v7nS1.14265

Authors

Ubedullah Bughio Senior Registrar, Asian Institute of Medical Science Hyderabad, Sindh, Pakistan
Adil Hassan Chang Senior Registrar, Asian Institute of Medical Science Hyderabad, Sindh, Pakistan
Rahmatullah Bhatti Assistant Professor, Asian Institute of Medical Science Hyderabad, Sindh, Pakistan
Bushra Kadir Senior Registrar, Asian Institute of Medical Science Hyderabad, Sindh, Pakistan
Muhammad Sadik Memon Professor, Asian Institute of Medical Science Hyderabad, Sindh, Pakistan
Saadat Ali Assistant Professor, Asian Institute of Medical Science Hyderabad, Sindh, Pakistan
Mashooque Samejo Resident, Asian Institute of Medical Science Hyderabad, Sindh, Pakistan
Sidra Dars Resident, Asian Institute of Medical Science Hyderabad, Sindh, Pakistan

Keywords:

Hepatitis C, Hepatocellular Carcinoma, Directly Acting Viral Agents, Sustained virologic Response

Abstract

Background and Aims: Hepatitis C infection is one of leading causes of liver cirrhosis and a considerable proportion of hepatocellular carcinoma worldwide. Despite the very high efficacy of Directly Acting Viral Agents (DAAs) on clearance of hepatitis C their role remains controversial on development of Hepatocellular Carcinoma. The Aim of this study is to analyze hepatocellular occurrence in hepatitis C patients after achieving Sustained virologic response on directly acting viral agent. Methods and Material: It is prospective study conducted on outpatients in the Hepato-gastroenterology department of Asian Institute of Medical Science Hospital Hyderabad from 21-10-2018 to 20-04-2019. All patients who fulfilled the criteria were enrolled, their baseline demographic characteristics, Child Pugh Class, MELD score, alpha-fetoprotein level and Ultrasound liver before and after treatment collected. Duration of DAAs treatment and type of DAAs used also noted. Hepatocellular carcinoma labelled when Triphasic CT scan liver shows typical characters of hepatocellular carcinoma i.e. arterial phase hyperenhancement and delayed washout on portal and venous phase or ultrasound liver shows focal liver lesion with alpha-fetoprotein level more than 300ng/ml. Results: One hundred fifty-seven patients of chronic hepatitis C enrolled in the study after exclusion criteria.

Downloads

Download data is not yet available.

References

Asselah T, Boyer N, Saadoun D, Martinot MP, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016 Jan;36 Suppl 1:47-57.

Majumdar A; Kitson MT; Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43(12):1276-92.

Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology 2012;142:1274-8

Spârchez Z, Mocan T.Hepatocellular Carcinoma Occurrence and Recurrence after Antiviral Treatment in HCV Related Cirrhosis. Are Outcomes Different after Direct Antiviral Agents? A Review. J Gastrointestin Liver Dis. 2017 Dec;26(4):403-10.

Janjua NZ, Chong M, Kuo M, Woods R, Wong J, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatology 2017;66:504-13.

Brown JL. Interferon therapy reduces the risk for hepatocellular carcinoma. Gut 2000;47:610-1.

Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005;40:148-56.

Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, et al. Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus-Related Cirrhosis. Clin Gastroenterol H 2010;8:192-9.

Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.

Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol 2016;65:663-5

Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S etal. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016 Oct;65(4):719-26

Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, StauberR et.al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. j.jhep.2016.06.009

Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, Pereira Pet.al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol. 2016 Nov;65(5):1070-71.

Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni Pet.al Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treatedwith direct-acting antivirals. J Hepatol. 2016 Oct;65(4):727-33.

Zeng QL, Li ZQ, Liang HX, Xu GH, Li CX, Zhang DW, Li Wet.al.Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming? J Hepatol. 2016 Nov;65(5):1068-69.

Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 Oct;153(4):996-1005.

Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. HepatitisC virus genotype 1b as a major risk factor associated with hepatocellularcarcinoma in patients with cirrhosis: a seventeen-year prospective cohortstudy. Hepatology 2007;46:1350–1356. doi: 10.1002/hep.21826.

Editorial: Non-A, non-B? Lancet 1975; 2: 64-65

Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science1989; 244: 359-62

Houghton M. Discovery of the hepatitis C virus. Liver Int 2009; 29 Suppl 1: 82-88

Ravi S, Axley P, Jones D, et al. Unusually high rates of hepatocellularcarcinoma after treatment with direct-actingantiviral therapy forhepatitis C related cirrhosis. Gastroenterology. 2017;152:911‐912.